Just In
- 3 hrs ago Daily Horoscope, 29 March 2024: Gemini Businessmen Should Be Careful, Leo May Not Feel Well Today
- 7 hrs ago Aditi Rao Hydari's 8 Tips for Glowing Skin: A Celebrity Skincare Routine Unveiled, Bonus Tips Included!
- 8 hrs ago April 2024 Health Horoscope: Know How This Month Will Affect Zodiac Signs In Terms Of Wellness
- 9 hrs ago Good Friday 2024: Wishes, Messages, Greetings, Texts, Images, Quotes, WhatsApp, And FB Status
Don't Miss
- Movies Aadujeevitham Box Office Collection Day 2 Prediction: Prithviraj & Blessy's Film Continues Strong Performance
- Finance 1:1 Bonus: Tata's 35-Year-Old Tech Company Makes Big Announcement; Stock May Rise By Rs 1,070 In 30 Days
- Sports IPL 2024: RR replace Prasidh Krishna with Keshav Maharaj, KKR name 16-year-old spinner in place of Mujeeb Ur Rahman
- News Jailed Gangster-Turned-Politician Mukhtar Ansari Dies Of Heart Attack
- Automobiles Xiaomi SU7 Electric Car Launched – May End Apple Inc.
- Technology HONOR Pad 9 With Bluetooth Keyboard Up For Grabs At Rs 22,499 in India
- Education RSMSSB Junior Instructor Recruitment 2024; Apply online for 2500 Posts, Check out for more details
- Travel Explore Tamil Nadu's Diverse Wedding Venues
New anti-diabetic agent from Reddy's Labs beibng tested
Hyderabad, Dec 26 (UNI) An anti-diabetic agent that works through new pathways, discovered by Dr Reddy's Laboratories and taken up for development by Perlecan Pharma, is undergoing Phase I clinical trials in the Netherlands.
The agent, DRL 16536, works by activating the biological pathways responsible for beneficial effects of exercise. Targeting the exercise pathway using the drug has lowered glucose and lipid values significantly in pre-clinical trials. It has additional benefit of weight loss.
Current treatment options for Type 2 diabetes work through other mechanisms and might not provide the overall beneficial clinical effects needed, which encompass glycemic control, lipid control and body weight loss, a statement from the two organisations here said.
DRL 16536 has been extensively studied in pre-clinical pharmacokinetic and toxicology experiment. It has demonstrated good oral bioavailability in animal models with adequate safety established in toxicology studies, it said.
The
Phase
I
clinical
trials
would
test
the
safety
and
tolerability
of
DRL-16536
in
healthy
volunteers.
Chairman,
Perlecan
Pharma
and
Founder-Chairman,
Dr
Reddy's
Laboratories,
Dr
K
Anji
Reddy
said
in
the
statement
that
'DRL
16536
is
the
fourth
asset
from
Perlecan
and
the
third
''first-in-class'' compound
from
Dr
Reddy's
discovery
research,
to
go
into
clinical
development.
With
the
experience
gained
in
modulation
of
this
target,
we
at
Dr
Reddy's
are
confident
of
discovering
drugs
for
prevention
and
treatment
of
metabolic
syndromes.'